Astera Labs Announces Financial Results for the Second Quarter of Fiscal Year 2024

Employer payroll taxes related to stock-based compensation resulting from our IPO

We exclude employer payroll taxes related to the time-based vesting and net settlement of restricted stock units in connection with our initial public offering (the “IPO”), because this does not correlate to the operation of our business. We believe that excluding this item provides meaningful supplemental information regarding operational performance given the amount of employer payroll tax-related items on employee stock transactions was immaterial prior to our IPO.

Income Tax effect

This represents the impact of the non-GAAP adjustments on an after-tax basis in connection with the presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share. This approach is designed to enhance investors’ ability to understand the impact of our non-GAAP tax expense on its current operations, provide improved modeling accuracy, and substantially reduce fluctuations caused by GAAP to non-GAAP adjustments.

Pro-forma non-GAAP weighted-average shares to compute non-GAAP net income (loss)

We present pro-forma non-GAAP weighted-average shares, assuming the redeemable convertible preferred stock is converted from the beginning of each respective periods presented, to provide meaningful supplemental information regarding EPS trend on a consistent basis. All of our outstanding redeemable preferred stock converted into the equivalent number of shares of common stock in connection with our IPO.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements based on Astera Labs' current expectations. The words "believe", "estimate", "expect", "intend", "anticipate", "plan", "project", "will", and similar phrases as they relate to Astera Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Astera Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements include but are not limited to, statements regarding our future operating results, financial position and guidance, our business strategy and plans, our objectives for future operations, including the success of our global footprint expansion, our development or delivery of new or enhanced products and anticipated results of those products for our customers, our competitive positioning, technological capabilities and plans, and macroeconomic trends in cloud and AI infrastructure. A variety of risks and factors that are beyond our control could cause actual results to differ materially from those in the forward-looking statements including, without limitation: the competitive and cyclical nature of the semiconductor industry; the concentration of our customer base; the continued demand for AI; the challenging macroeconomic environment, including disruptions in the financial services industry; risks that demand and the supply chain may be adversely affected, including by military conflict (such as between Russia/Ukraine and Israel/Hamas), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with managing international activities (including trade barriers, particularly with respect to China); absence of long-term commitments from customers; risks that Astera Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; stock price volatility; information technology risks, including cyber-attacks against Astera Labs' products and its networks; and other risks and uncertainties that are detailed under the caption “Risk Factors” and elsewhere in our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) and the other SEC filings and reports Astera Labs may make from time to time. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor(s) may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. Astera Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

About Astera Labs

Our PCIe, CXL and Ethernet semiconductor-based connectivity solutions are purpose-built to unleash the full potential of accelerated computing at cloud-scale. Inspired by trusted partnerships with hyperscalers and the data center ecosystem, we are an innovation leader of products that are customizable, interoperable, and reliable. Discover how we are transforming AI and modern data-driven applications at www.asteralabs.com.

ASTERA LABS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(In thousands)

 

 

 

June 30,
2024

 

December 31,
2023

Assets

 

 

 

 

Current assets

 

 

 

 

Cash and cash equivalents

 

$

421,076

 

 

$

45,098

 

Marketable securities

 

 

409,919

 

 

 

104,215

 

Accounts receivable, net

 

 

22,233

 

 

 

8,335

 

Inventory

 

 

28,572

 

 

 

24,095

 

Prepaid expenses and other current assets

 

 

9,445

 

 

 

4,064

 

Total current assets

 

 

891,245

 

 

 

185,807

 

Property and equipment, net

 

 

21,821

 

 

 

4,712

 

Other assets

 

 

2,449

 

 

 

5,773

 

Total assets

 

$

915,515

 

 

$

196,292

 

 

 

 

 

 

Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

 

 

 

Current liabilities

 

 

 

 

Accounts payable

 

$

14,595

 

 

$

6,337

 

Accrued expenses and other current liabilities

 

 

49,478

 

 

 

28,742

 

Total current liabilities

 

 

64,073

 

 

 

35,079

 

Other liabilities

 

 

6,190

 

 

 

3,787

 

Total liabilities

 

 

70,263

 

 

 

38,866

 

Commitments and contingencies

 

 

 

 

Redeemable convertible preferred stock

 

 

 

 

 

255,127

 

Stockholders’ equity (deficit)

 

 

 

 

Common stock

 

 

16

 

 

 

4

 

Additional paid-in capital

 

 

1,071,504

 

 

 

27,411

 

Accumulated other comprehensive (loss) income

 

 

(352

)

 

 

259

 

Accumulated deficit

 

 

(225,916

)

 

 

(125,375

)

Total stockholders’ equity (deficit)

 

 

845,252

 

 

 

(97,701

)

Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)

 

$

915,515

 

 

$

196,292

 

ASTERA LABS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,
2024

 

March 31,
2024

 

June 30,
2023

 

June 30,
2024

 

June 30,
2023

Revenue

 

$

76,850

 

 

$

65,258

 

 

$

10,688

 

 

$

142,108

 

 

$

28,352

 

Cost of revenue

 

 

16,996

 

 

 

14,738

 

 

 

2,249

 

 

 

31,734

 

 

 

15,655

 

Gross profit

 

 

59,854

 

 

 

50,520

 

 

 

8,439

 

 

 

110,374

 

 

 

12,697

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

40,089

 

 

 

53,558

 

 

 

17,860

 

 

 

93,647

 

 

 

33,127

 

Sales and marketing

 

 

22,076

 

 

 

55,510

 

 

 

5,097

 

 

 

77,586

 

 

 

9,490

 

General and administrative

 

 

22,036

 

 

 

24,419

 

 

 

3,095

 

 

 

46,455

 

 

 

6,620

 

Total operating expenses

 

 

84,201

 

 

 

133,487

 

 

 

26,052

 

 

 

217,688

 

 

 

49,237

 

Operating loss

 

 

(24,347

)

 

 

(82,967

)

 

 

(17,613

)

 

 

(107,314

)

 

 

(36,540

)

Interest income

 

 

10,264

 

 

 

2,554

 

 

 

1,555

 

 

 

12,818

 

 

 

3,151

 

Loss before income taxes

 

 

(14,083

)

 

 

(80,413

)

 

 

(16,058

)

 

 

(94,496

)

 

 

(33,389

)

Income tax (benefit) provision

 

 

(6,537

)

 

 

12,582

 

 

 

3,946

 

 

 

6,045

 

 

 

4,069

 

Net loss

 

$

(7,546

)

 

$

(92,995

)

 

$

(20,004

)

 

$

(100,541

)

 

$

(37,458

)

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common stockholders:

 

 

 

 

Basic and diluted

 

$

(0.05

)

 

$

(1.77

)

 

$

(0.55

)

 

$

(0.97

)

 

$

(1.03

)

Weighted-average shares used in calculating net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

155,199

 

 

 

52,532

 

 

 

36,567

 

 

 

103,865

 

 

 

36,199

 

ASTERA LABS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(In thousands)

 

 

 

Six Months Ended

 

 

June 30,
2024

 

June 30,
2023

Cash flows from operating activities

 

 

 

 

Net loss

 

$

(100,541

)

 

$

(37,458

)

Adjustments to reconcile net loss to net cash provided by (used in) operating activities

 

 

 

 

Stock-based compensation

 

 

140,835

 

 

 

4,669

 

Inventory write-downs

 

 

1,493

 

 

 

9,733

 

Depreciation

 

 

1,331

 

 

 

763

 

Non-cash operating lease expense

 

 

1,106

 

 

 

536

 

Warrants contra revenue

 

 

443

 

 

 

127

 

Accretion of discounts on marketable securities

 

 

(1,637

)

 

 

(640

)

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable, net

 

 

(13,898

)

 

 

9,081

 

Inventory

 

 

(5,970

)

 

 

1,374

 

Prepaid expenses and other assets

 

 

(5,396

)

 

 

223

 

Accounts payable

 

 

5,831

 

 

 

(7,745

)

Accrued expenses and other liabilities

 

 

10,930

 

 

 

(6,844

)

Operating lease liability

 

 

(1,062

)

 

 

(600

)

Net cash provided by (used in) operating activities

 

 

33,465

 

 

 

(26,781

)

 

 

 

 

 

Cash flows from investing activities

 

 

 

 

Purchases of property and equipment

 

 

(2,100

)

 

 

(1,014

)

Purchases of marketable securities

 

 

(345,756

)

 

 

(27,274

)

Maturities of marketable securities

 

 

20,776

 

 

 

18,000

 

Sales of marketable securities

 

 

20,358

 

 

 

54,749

 

Net cash (used in) provided by investing activities

 

 

(306,722

)

 

 

44,461

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions

 

 

672,198

 

 

 

 

Payment of deferred offering costs

 

 

(4,801

)

 

 

 

Tax withholding related to net share settlements of restricted stock units

 

 

(20,111

)

 

 

 

Proceeds (payments) from exercises of stock options, net of repurchases

 

 

1,949

 

 

 

(87

)

Net cash provided by (used in) financing activities

 

 

649,235

 

 

 

(87

)

Net increase in cash and cash equivalents

 

 

375,978

 

 

 

17,593

 

Cash and cash equivalents

 

 

 

 

Beginning of the period

 

 

45,098

 

 

 

76,088

 

End of the period

 

$

421,076

 

 

$

93,681

 

ASTERA LABS, INC.

 

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (Unaudited)

(In thousands, except percentages and per share amounts)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,
2024

 

March 31,
2024

 

June 30,
2023

 

June 30,
2024

 

June 30,
2023

GAAP gross profit

 

$

59,854

 

 

$

50,520

 

 

$

8,439

 

 

$

110,374

 

 

$

12,697

 

Stock-based compensation expense upon IPO (1)

 

 

 

 

 

516

 

 

 

 

 

 

516

 

 

 

 

Stock-based compensation expense

 

 

84

 

 

 

12

 

 

 

2

 

 

 

96

 

 

 

7

 

Non-GAAP gross profit

 

$

59,938

 

 

$

51,048

 

 

$

8,441

 

 

$

110,986

 

 

$

12,704

 

 

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

 

77.9

%

 

 

77.4

%

 

 

79.0

%

 

 

77.7

%

 

 

44.8

%

Stock-based compensation expense upon IPO (1)

 

 

 

 

 

0.8

 

 

 

 

 

 

0.3

 

 

 

 

Stock-based compensation expense

 

 

0.1

 

 

 

 

 

 

 

 

 

0.1

 

 

 

 

Non-GAAP gross margin

 

 

78.0

%

 

 

78.2

%

 

 

79.0

%

 

 

78.1

%

 

 

44.8

%

 

 

 

 

 

 

 

 

 

 

 

GAAP operating loss

 

$

(24,347

)

 

$

(82,967

)

 

$

(17,613

)

 

$

(107,314

)

 

$

(36,540

)

Stock-based compensation expense upon IPO (1)

 

 

 

 

 

88,873

 

 

 

 

 

 

88,873

 

 

 

 

Stock-based compensation expense

 

 

43,067

 

 

 

8,895

 

 

 

2,672

 

 

 

51,962

 

 

 

4,669

 

Employer payroll tax related to stock-based compensation from IPO (2)

 

 

 

 

 

1,072

 

 

 

 

 

 

1,072

 

 

 

 

Non-GAAP operating income (loss)

 

$

18,720

 

 

$

15,873

 

 

$

(14,941

)

 

$

34,593

 

 

$

(31,871

)

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss

 

$

(7,546

)

 

$

(92,995

)

 

$

(20,004

)

 

$

(100,541

)

 

$

(37,458

)

Stock-based compensation expense upon IPO (1)

 

 

 

 

 

88,873

 

 

 

 

 

 

88,873

 

 

 

 

Stock-based compensation expense

 

 

43,067

 

 

 

8,895

 

 

 

2,672

 

 

 

51,962

 

 

 

4,669

 

Employer payroll tax related to stock-based compensation from IPO (2)

 

 

 

 

 

1,072

 

 

 

 

 

 

1,072

 

 

 

 

Income tax effect (3)

 

 

(13,296

)

 

 

8,485

 

 

 

 

 

 

(4,811

)

 

 

 

Non-GAAP net income (loss)

 

$

22,225

 

 

$

14,330

 

 

$

(17,332

)

 

$

36,555

 

 

$

(32,789

)

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share attributable to common stockholders:

 

 

 

 

GAAP - basic and diluted

 

$

(0.05

)

 

$

(1.77

)

 

$

(0.55

)

 

$

(0.97

)

 

$

(1.03

)

Pro forma Non-GAAP - diluted

 

$

0.13

 

 

$

0.10

 

 

$

(0.14

)

 

$

0.23

 

 

$

(0.26

)

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to compute net loss per share attributable to common stockholders:

 

 

 

 

GAAP - basic and diluted

 

 

155,199

 

 

 

52,532

 

 

 

36,567

 

 

 

103,865

 

 

 

36,199

 

Pro forma Non-GAAP - diluted (4)

 

 

175,279

 

 

 

147,514

 

 

 

127,458

 

 

 

162,378

 

 

 

127,090

 

_______________________

(1) Stock-based compensation expense recognized in connection with the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

(2) Employer payroll taxes related to the time-based vesting and settlement of RSUs, that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.

(3) The income tax effect represents the impact of the non-GAAP adjustments on an after-tax basis in connection with the presentation of non-GAAP net income (loss) and non-GAAP net income (loss) per diluted share. For the three months ended June 30, 2024 and March 31, 2024, the non-GAAP tax rates were approximately of 23% and 22%, respectively. For the six months ended June 30, 2024, the non-GAAP tax rate was approximately 23%. The adjustments for the three and six months ended June 30, 2023 were not material.

(4) We present the pro-forma non-GAAP weighted average shares to provide meaningful supplemental information of comparable shares for each periods presented. The pro forma weighted average shares is calculated as follows:

 

 

Three Months Ended

 

Six Months Ended

 

 

June 30,
2024

 

March 31,
2024

 

June 30,
2023

 

June 30,
2024

 

June 30,
2023

Shares used to compute GAAP net loss per share attributable to common stockholders - diluted

 

155,199

 

52,532

 

36,567

 

103,865

 

36,199

Weighted average effect of the assumed conversion of redeemable convertible preferred stock from the beginning of the periods

 

 

78,905

 

90,891

 

40,451

 

90,891

Effect of dilutive equivalent shares

 

20,080

 

16,077

 

 

18,062

 

Shares used to compute pro forma non-GAAP net income (loss) per share- diluted

 

175,279

 

147,514

 

127,458

 

162,378

 

127,090

ASTERA LABS, INC.

 

SUPPLEMENTAL FINANCIAL INFORMATION

STOCK-BASED COMPENSATION EXPENSE (Unaudited)

(In thousands)

 

 

Three Months Ended

 

Six Months Ended

 

June 30,
2024

 

March 31,
2024

 

June 30,
2023

 

June 30,
2024

 

June 30,
2023

Cost of revenue

$

84

 

$

528

 

$

2

 

$

612

 

$

7

Research and development

 

12,971

 

 

30,007

 

 

1,672

 

 

42,978

 

 

3,351

Sales and marketing

 

15,758

 

 

49,258

 

 

694

 

 

65,016

 

 

695

General and administrative

 

14,254

 

 

17,975

 

 

304

 

 

32,229

 

 

616

Total stock-based compensation expense (1)

$

43,067

 

$

97,768

 

$

2,672

 

$

140,835

 

$

4,669

____________________

(1) Stock-based compensation expense recognized during the three months ended March 31, 2024 and six months ended June 30, 2024 included $88.9 million of cumulative stock-based compensation expense related to the time-based vesting and settlement of RSUs that had previously met the time-based vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.





© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us
ShareCG™ is a trademark of Internet Business Systems, Inc.

Report a Bug Report Abuse Make a Suggestion About Privacy Policy Contact Us User Agreement Advertise